<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The metabolism of endogenous <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> P(AA) was investigated in activated neutrophils from 20 patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, 20 with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, and 25 healthy volunteers </plain></SENT>
<SENT sid="1" pm="."><plain>1-14C-P(AA) was incorporated into intracellular pools of <z:chebi fb="1" ids="16247">phospholipids</z:chebi> prior to activation of the cells with <z:chebi fb="0" ids="24869">ionophore</z:chebi> A23187 and analyses of released <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> metabolites by thin layer chromatography </plain></SENT>
<SENT sid="2" pm="."><plain>Total release of radioactivity expressing the release of <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> and its metabolites, was equal in the experimental and control groups, which suggests a <z:mpath ids='MPATH_458'>normal</z:mpath> substrate availability </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, there was a marked increase in the relative release of <z:chebi fb="0" ids="25029">leucotriene</z:chebi> B4 (<z:chebi fb="0" ids="15647">LTB4</z:chebi>) and its omega-oxidation products, <z:chebi fb="0" ids="15646">20-hydroxy-LTB4</z:chebi> (20-OH-<z:chebi fb="0" ids="15647">LTB4</z:chebi>) and <z:chebi fb="0" ids="27562">20-carboxy-LTB4</z:chebi> (20-COOH-<z:chebi fb="0" ids="15647">LTB4</z:chebi>), with <z:chebi fb="0" ids="15647">LTB4</z:chebi> values exceeding the reference interval in seven of 20 patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo>, median 8.7%, and in six of 20 patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, median 7.7%, as compared with a median of 5.3% in healthy volunteers </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, a decreased release of unmetabolised <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>, correlating inversely with the release of <z:chebi fb="0" ids="15647">LTB4</z:chebi> in <z:hpo ids='HP_0000001'>all</z:hpo> experimental and control groups, and <z:mpath ids='MPATH_458'>normal</z:mpath> values for the production of other metabolites of <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>--for example, 5-hydroxyeicosatetraenoic acid (<z:chebi fb="0" ids="28209">5-HETE</z:chebi>) and 12-hydroxyheptadecatrienoic acid (HHT), point to an enzymatic abnormality such as increased activity of <z:chebi fb="0" ids="25029">leucotriene</z:chebi> B synthetase </plain></SENT>
<SENT sid="5" pm="."><plain>An increased capacity for release of <z:chebi fb="0" ids="15647">LTB4</z:chebi>, the major pro-inflammatory metabolite of <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> lipoxygenation by polymorphonuclear leucocytes, may contribute to perpetuation of the <z:mp ids='MP_0001845'>inflammation</z:mp> and to tissue destruction in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings agree with previous reports of an increased release of <z:chebi fb="0" ids="15647">LTB4</z:chebi> by the colonic mucosa in this condition </plain></SENT>
</text></document>